Tumor Biology Department Metrics

CLINICAL TRIAL 17971
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Condition: Thoracic
Intervention: Not Applicable ()

CLINICAL TRIAL 17970
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Condition: Thoracic
Intervention: Crizotinib (); Not Applicable (); Placebo (); Xalkori (Crizotinib)

CLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 19319
InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Condition: Genitourinary
Intervention: Ifosfamide (); Not Applicable (); Radiotherapy (); Taxol (paclitaxel); cisplatin (); paclitaxel ()

CLINICAL TRIAL 19950
Linking the Skin and Gut Microbiome to Immunosuppression in Skin Cancer
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 20003
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)
Condition: Thoracic
Intervention: ALT-803 (); AMG 510 (Sotorasib); Alimta (Pemetrexed); Dexamethasone (); Folic Acid (); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Taxotere (docetaxel); Vitamin B12 (); docetaxel (); gemcitabine ()

CLINICAL TRIAL 20561
Randomized Trial of Prolonged Use of Negative Pressure Wound Therapy in Patients Undergoing Surgical Procedures for the Management of Gastrointestinal Malignancies
Condition: Gastrointestinal Tumor
Intervention:

CLINICAL TRIAL 20767
Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxol (paclitaxel); carboplatin (); cisplatin (); gemcitabine (); paclitaxel ()

CLINICAL TRIAL 20964
A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations
Condition: Multiple
Intervention: Faslodex (fulvestrant); Herceptin (Trastuzumab); Trastuzumab (); Tucatinib (); fulvestrant (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20938
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Condition: Thoracic
Intervention: Not Applicable (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 21180
A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)
Condition: Multiple
Intervention: GDC-0199 (Venetoclax); ICT01 (); Not Applicable (); Pembrolizumab (Keytruda); Venetoclax (); azacitidine (5-azacitidine)

CLINICAL TRIAL 21157
A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study To Investigate The Safety, Pharmacokinetics And Preliminary Efficacy Of Intravenous NBF-006 In Patients With Non-Small Cell Lung, Pancreatic, Or Colorectal Cancer Followed By A Dose Expansion Study In Patients With KRAS-Mutated Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: NBF-006 ()

CLINICAL TRIAL 21184
Thoracic Program Trial Selection Protocol
Condition: Thoracic
Intervention:

CLINICAL TRIAL 21228
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Pembrolizumab versus Docetaxel with or without Ramucirumab in Patients with Previously Treated Non-Small Cell Lung Cancer (Acclaim 2)
Condition: Thoracic
Intervention: GPX-001 (); IMC-1121B (Ramucirumab); Pembrolizumab (Keytruda); Ramucirumab (); Taxotere (docetaxel); docetaxel ()

CLINICAL TRIAL 21273
A Randomized, Pilot Study to Evaluate the Molecular and Cellular Response to Treatment with Nivolumab with either Adjuvant Ipilimumab or Relatlimab in Adult Patients with Surgically Resectable Melanoma Brain Metastases
Condition: Neurologic Oncology
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Radiotherapy (); Relatlimab (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21534
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Condition: Thoracic
Intervention: AMP-514 (Durvalumab); Alimta (Pemetrexed); Durvalumab (); MEDI4736 (Durvalumab); Paraplatin (carboplatin); Pemetrexed (); Radiotherapy (); Taxol (paclitaxel); carboplatin (); cisplatin (); etoposide (); paclitaxel ()

CLINICAL TRIAL 21587
A Dose-escalation Study of the Safety and Pharmacology of DAN 222 in Subjects with Metastatic Breast Cancer
Condition: Breast
Intervention: DAN-222 (); Niraparib ()

CLINICAL TRIAL 21609
A Phase I Dose Escalation And Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, And Anti-Tumor Activity Of PF-07260437 In Advanced Or Metastatic Solid Tumors
Condition: Breast
Intervention: Dexamethasone (); Diphenhydramine (); PF-07260437 (); acetaminophen ()

CLINICAL TRIAL 20003-TREATMENT
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Treatment Substudies)
Condition: Thoracic
Intervention: AG-014447 (Rucaparib); ALT-803 (); AMG 510 (Sotorasib); Alimta (Pemetrexed); Avelumab (); BMN-673 (Talazoparib); CO-338 (Rucaparib); Dexamethasone (); Folic Acid (); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); MSB00100718C (Avelumab); PF-01367338-BW (Rucaparib); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Rucaparib (); Selpercatinib (); Talazoparib (); Taxotere (docetaxel); Vitamin B12 (); carboplatin (); docetaxel (); gemcitabine ()

• Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Gwede, C.,Project PI:Meade, C.
• Determinants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/Aging Cancer)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Islam, J.
• Moffitt Cancer Center Support Grant Years 24-27
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Kanetsky, P.,Project PI:Kissil, J.,Project PI:Brandon, T.,Project PI:Conejo-Garcia, J.,Project PI:Duckett, D.,Project PI:Gray, J.,Project PI:Jim, H.,Project PI:Locke, F.,Core PI/Director:Springer, B.,Core PI/Director:Vadaparampil, S.,Core PI/Director:Wright, K.,Core PI/Director:Rodriguez, P.
• The role of Accelerated Biological Aging in HIV control and Non-AIDS-defining Cancer Risk (Biospecimens/Biocohort)
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Coghill, A.
• Cancer Clinical Investigator Team Leadership Award (CCITLA) P30 Administrative Supplement
  Sponsor: Nat Institutes of Health
  PI (Contact):Cleveland, J.,PI:Eroglu, Z.
• 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
  Sponsor: Nat Institutes of Health
  PI (Contact):Munoz-Antonia, T.,PI:Sullivan, D.
• Local and Systemic Control of Multiple Myeloma Colonization and Growth by MMP-13
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• Enhancing TIL populations and immunotherapy efficacy in melanoma by modulating fucosylation
  Sponsor: Nat Institutes of Health
  PI:Le-Lau, E.
• New Therapeutic Vulnerabilities for Aggressive B-Cell Lymphoma
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• Defining bone ecosystem effects on metastatic prostate cancer evolution and treatment response using an integrated mathematical modeling approach
  Sponsor: Nat Institutes of Health
  PI (Contact):Lynch, C.,PI (MPI):Basanta Gutierrez, D.
• State of FL-License Plate Funds
  Sponsor: State of Florida
  PI:Cleveland, J.
• Targeted degradation of RNAs by using small molecules
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.
• CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancer
  Sponsor: Nat Institutes of Health
  PI:Chellappan, S.
• Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis
  Sponsor: Nat Institutes of Health
  PI:Smalley, K.
• Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases
  Sponsor: Nat Institutes of Health
  PI:Smalley, K.
• Functional characterization of prostate cancer risk loci by high throughput sequencing
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• St of FL Appropriation-CET Developmental Funds-12
  Sponsor: State of Florida
  PI (Contact):Cleveland, J.,Project PI:Anderson, A.
• St of FL Appropriation-CMRC Developmental Funds-10
  Sponsor: State of Florida
  PI (Contact):Cleveland, J.,PI (MPI):Smalley, K.
• St of FL Appropriation-CIRC Developmental Funds- 09
  Sponsor: State of Florida
  PI (Contact):Cleveland, J.,PI (MPI):Giuliano, A.
• St of FL Appropriation-Lung CoE Developmental Funds-11
  Sponsor: State of Florida
  PI (Contact):Cleveland, J.,PI (MPI):Haura, E.
• Investigating the role of melanin-carbonyl-DNA and melanin-carbonyl-protein adducts in melanoma pathogenesis
  Sponsor: Moffitt Cancer Center
  PI (Contact):Premi, S.,PI:Boyle, T.
• Cell free nucleic acid-based biomarkers in advanced prostate cancer
  Sponsor: Nat Institutes of Health
  PI (MPI):Wang, L.
• Defining and Targeting Epigenetic Plasticity-Driven Drug Resistance and Immune Escape in Melanoma
  Sponsor: Nat Institutes of Health
  PI:Smalley, K.
• State Cancer Center Funds-
  Sponsor: State of Florida
  PI:Cleveland, J.
• Defining and targeting the epigenetic programs involved in melanoma development
  Sponsor: Nat Institutes of Health
  PI:Smalley, K.
• Role of ULK3 in Sensitive End Refractory Multiple Myeloma
  Sponsor: Nat Institutes of Health
  PI:Lynch, C.
• The trouble with testosterone: delineating how androgen drives melanoma invasiveness and metastasis via fucosylation-regulated cellular adhesion
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Le-Lau, E.
• Developing ULK3 inhibitors for Multiple Myeloma
  Sponsor: Moffitt Cancer Center
  PI (Contact):Lynch, C.,PI:Lawrence, N.
• Uncovering causal protein markers to characterize prostate cancer etiology and improve risk prediction in Africans and Europeans
  Sponsor: Nat Institutes of Health
  PI:Wang, L.
• Proposal to evaluate pan-Ras/NRAS inhibitors in melanoma and melanoma brain metastases
  Sponsor: Revolution Medicines Inc
  PI:Smalley, K.
• The role of melanin-carbonyls in regulating melanoma progression and therapeutic resistance
  Sponsor: Moffitt Cancer Center
  PI:Premi, S.
• Modulating dendritic cell (DC) polarization and biology with L-fucose to enhance immunotherapy efficacy in melanoma
  Sponsor: Moffitt Cancer Center
  PI:Le-Lau, E.,CO-PI:Czerniecki, B.
• Single cell analysis of melanoma brain metastases following neoadjuvant immunotherapy treatment.
  Sponsor: Moffitt Cancer Center
  PI:Smalley, K.
• Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology
  Sponsor: Nat Institutes of Health
  PI:Amelio, A.
• Administrative Supplement to the Cancer Center Support Grant to Strengthen the Research, Training and Outreach Capacity of the Geographic Management Cancer Health Disparities Program
  Sponsor: Nat Institutes of Health
  PI:Cleveland, J.,Project PI:Gwede, C.,Project PI:Meade, C.

• Ilter D, Drapela S, Schild T, Ward NP, Adhikari E, Low V, Asara J, Oskarsson T, Lau EK, DeNicola GM, McReynolds MR, Gomes AP. NADK-mediated de novo NADP(H) synthesis is a metabolic adaptation essential for breast cancer metastasis. Redox Biol. 2023 May.61:102627. Pubmedid: 36841051. Pmcid: PMC9982641.
• Malapelle U, Borralho P, Wang L, Schmitt F. Editorial: Cancer diagnostics in solid tumors-from pathology to precision oncology. Front Mol Biosci. 2023 Feb.10:1150641. Pubmedid: 36895807. Pmcid: PMC9990903.
• Velayutham S, Seal T, Danthurthy S, Zaias J, Smalley KSM, Minond D. In Vivo Acute Toxicity Studies of Novel Anti-Melanoma Compounds Downregulators of hnRNPH1/H2. Biomolecules. 2023 Feb.13(2). Pubmedid: 36830718. Pmcid: PMC9953269.
• Medina E, Easa Y, Lester DK, Lau EK, Sprinzak D, Luca VC. Structure of the planar cell polarity cadherins Fat4 and Dachsous1. Nat Commun. 2023 Feb.14(1):891. Pubmedid: 36797229. Pmcid: PMC9935876.
• Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy. Nat Cancer. 2023 Feb.4(2):222-239. Pubmedid: 36690875. Pmcid: PMC9970875.
• Srivastava J, Young MM, Yadav VK, Phadatare PR, Meyer TA, Chaudhuri RK, Premi S. The Role of Acetyl Zingerone and Its Derivatives in Inhibiting UV-Induced, Incident, and Delayed Cyclobutane Pyrimidine Dimers. Antioxidants (Basel). 2023 Jan.12(2). Pubmedid: 36829837. Pmcid: PMC9952391.
• Soupir AC, Tian Y, Stewart PA, Nunez-Lopez YO, Manley BJ, Pellini B, Bloomer AM, Zhang J, Mo Q, Marchion DC, Liu M, Koomen JM, Siegel EM, Wang L. Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. Int J Mol Sci. 2023 Jan.24(3). Pubmedid: 36768152. Pmcid: PMC9916336.
• Patel KB, Padhya TA, Huang J, Hernandez-Prera JC, Li T, Chung CH, Wang L, Wang X. Plasma cell-free DNA methylome profiling in pre- and post-surgery oral cavity squamous cell carcinoma. Mol Carcinogen. 2023 Jan. Pubmedid: 36636912.
• Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan.613(7945):E3. Pubmedid: 36627494.
• Smalley KSM. Too Much Fuel on the Fire? Linking Obesity, Metabolism, and Melanoma Outcomes. Clin Cancer Res. 2023 Jan.29(1):5-7. Pubmedid: 36315002.
• Freischel AR, Teer JK, Luddy K, Cunningham J, Artzy-Randrup Y, Epstein T, Tsai KY, Berglund A, Cleveland JL, Gillies RJ, Brown JS, Gatenby RA. Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes. Cancers (Basel). 2022 Dec.15(1). Pubmedid: 36612014. Pmcid: PMC9817988.
• Zeng PYF, Cecchini MJ, Barrett JW, Shammas-Toma M, De Cecco L, Serafini MS, Cavalieri S, Licitra L, Hoebers F, Brakenhoff RH, Leemans CR, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort JC, Shaikh MH, Ryan SEB, Dawson A, Khan MI, Howlett CJ, Stecho W, Plantinga P, Daniela da Silva S, Hier M, Khan H, MacNeil D, Mendez A, Yoo J, Fung K, Lang P, Winquist E, Palma DA, Ziai H, Amelio AL, Li SS, Boutros PC, Mymryk JS, Nichols AC. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. EBioMedicine. 2022 Dec.86:104373. Pubmedid: 36442320. Pmcid: PMC9706534.
• Sriramareddy SN, Faião-Flores F, Emmons MF, Saha B, Chellappan S, Wyatt C, Smalley I, Licht JD, Durante MA, Harbour JW, Smalley KSM. HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma. Cancer Gene Ther. 2022 Dec.29(12):1840-1846. Pubmedid: 35332245. Pmcid: PMC9508287.
• Shaw TI, Zhao B, Li Y, Wang H, Wang L, Manley B, Stewart PA, Karolak A. Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients. Front Oncol. 2022 Nov.12:1051487. Pubmedid: 36505834. Pmcid: PMC9730332.
• Peng V, Cao S, Trsan T, Bando JK, Avila-Pacheco J, Cleveland JL, Clish C, Xavier RJ, Colonna M. Ornithine decarboxylase supports ILC3 responses in infectious and autoimmune colitis through positive regulation of IL-22 transcription. Proc Natl Acad Sci U S A. 2022 Nov.119(45):e2214900119. Pubmedid: 36279426. Pmcid: PMC9659397.
• Karz A, Dimitrova M, Kleffman K, Alvarez-Breckenridge C, Atkins MB, Boire A, Bosenberg M, Brastianos P, Cahill DP, Chen Q, Ferguson S, Forsyth P, Glitza Oliva IC, Goldberg SB, Holmen SL, Knisely JPS, Merlino G, Nguyen DX, Pacold ME, Perez-Guijarro E, Smalley KSM, Tawbi HA, Wen PY, Davies MA, Kluger HM, Mehnert JM, Hernando E. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2022 Nov.35(6):554-572. Pubmedid: 35912544.
• Zhang J, Gallaher J, Cunningham JJ, Choi JW, Ionescu F, Chatwal MS, Jain R, Kim Y, Wang L, Brown JS, Anderson AR, Gatenby RA. A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers (Basel). 2022 Oct.14(21). Pubmedid: 36358643. Pmcid: PMC9656891.
• Mandula JK, Chang S, Mohamed E, Jimenez R, Sierra-Mondragon RA, Chang DC, Obermayer AN, Moran-Segura CM, Das S, Vazquez-Martinez JA, Prieto K, Chen A, Smalley KSM, Czerniecki B, Forsyth P, Koya RC, Ruffell B, Cubillos-Ruiz JR, Munn DH, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. Cancer Cell. 2022 Oct.40(10):1145-1160.e9. Pubmedid: 36150390. Pmcid: PMC9561067.
• Ramos LD, Gomes TMV, Quintiliano SAP, Premi S, Stevani CV, Bechara EJH. Biological Schiff bases may generate reactive triplet carbonyls and singlet oxygen: A model study. Free Radical Bio Med. 2022 Oct.191:97-104. Pubmedid: 36049617.
• Hesterberg RS, Liu M, Elmarsafawi AG, Koomen JM, Welsh EA, Hesterberg SG, Ranatunga S, Yang C, Li W, Lawrence HR, Rodriguez PC, Berglund AE, Cleveland JL. TCR-Independent Metabolic Reprogramming Precedes Lymphoma-Driven Changes in T-cell Fate. Cancer Immunol Res. 2022 Oct.10(10):1263-1279. Pubmedid: 35969234. Pmcid: PMC9662872.
• Chang A, Chakiryan NH, Du D, Stewart PA, Zhang Y, Tian Y, Soupir AC, Bowers K, Fang B, Morganti A, Teer JK, Kim Y, Spiess PE, Chahoud J, Noble JD, Putney RM, Berglund AE, Robinson TJ, Koomen JM, Wang L, Manley BJ. Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. Eur Urol. 2022 Oct.82(4):354-362. Pubmedid: 35718636.
• Law V, Chen Z, Vena F, Smalley I, Macaulay R, Evernden BR, Tran N, Pina Y, Puskas J, Caceres G, Bayle S, Johnson J, Liu JKC, Etame A, Vogelbaum M, Rodriguez P, Duckett D, Czerniecki B, Chen A, Smalley KSM, Forsyth PA. A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma. Neurooncol. 2022 Oct.24(10):1673-1686. Pubmedid: 35213727. Pmcid: PMC9527526.
• Huang J, Du M, Soupir A, Wang L, Tan W, Kalari KR, Kilari D, Park J, Huang CC, Kohli M, Wang L. Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2022 Sep.14(19). Pubmedid: 36230636. Pmcid: PMC9562906.
• Thompson ZJ, Teer JK, Li J, Chen Z, Welsh EA, Zhang Y, Ayoubi N, Eroglu Z, Tan AC, Smalley KSM, Chen YA. Drepmel-A Multi-Omics Melanoma Drug Repurposing Resource for Prioritizing Drug Combinations and Understanding Tumor Microenvironment. Cells. 2022 Sep.11(18). Pubmedid: 36139469. Pmcid: PMC9497118.
• Murphy RM, Tasoulas J, Porrello A, Carper MB, Tsai YH, Coffey AR, Kumar S, Zeng PY, Schrank TP, Midkiff BR, Cohen S, Salazar AH, Hayward MC, Hayes DN, Olshan A, Gupta GP, Nichols AC, Yarbrough WG, Pecot CV, Amelio AL. Tumor Cell Extrinsic Synaptogyrin 3 Expression as a Diagnostic and Prognostic Biomarker in Head and Neck Cancer. Cancer Res Commun. 2022 Sep.2(9):987-1004. Pubmedid: 36148399. Pmcid: PMC9491693.
• Smalley I, Smalley KSM. Space Is the Place: Mapping the Cell-Cell Interactions That Predict Immunotherapy Responses in Melanoma. Cancer Res. 2022 Sep.82(18):3198-3200. Pubmedid: 36111402.
• He Y, Wei C, Sun Z, Cunningham JM, Wang L, Wei Z, Yang P. Genome-wide methylation profiling reveals differentially methylated genes in blood DNA of small-cell lung cancer patients. Precis Clin Med. 2022 Sep.5(3):pbac017. Pubmedid: 35875603. Pmcid: PMC9306013.
• Terajima M, Taga Y, Nakamura T, Guo HF, Kayashima Y, Maeda-Smithies N, Parag-Sharma K, Kim JS, Amelio AL, Mizuno K, Kurie JM, Yamauchi M. Lysyl hydroxylase 2 mediated collagen post-translational modifications and functional outcomes. Sci Rep. 2022 Aug.12(1):14256. Pubmedid: 35995931. Pmcid: PMC9395344.
• Kaler CJ, Dollar JJ, Cruz AM, Kuznetsoff JN, Sanchez MI, Decatur CL, Licht JD, Smalley KSM, Correa ZM, Kurtenbach S, Harbour JW. BAP1 Loss Promotes Suppressive Tumor Immune Microenvironment via Upregulation of PROS1 in Class 2 Uveal Melanomas. Cancers (Basel). 2022 Jul.14(15). Pubmedid: 35954340. Pmcid: PMC9367253.
• Carper MB, Goel S, Zhang AM, Damrauer JS, Cohen S, Zimmerman MP, Gentile GM, Parag-Sharma K, Murphy RM, Sato K, Nickel KP, Kimple RJ, Yarbrough WG, Amelio AL. Activation of the CREB Coactivator CRTC2 by Aberrant Mitogen Signaling promotes oncogenic functions in HPV16 positive head and neck cancer. Neoplasia. 2022 Jul.29:100799. Pubmedid: 35504112. Pmcid: PMC9065880.
• Yao Z, Brennan CK, Scipioni L, Chen H, Ng KK, Tedeschi G, Parag-Sharma K, Amelio AL, Gratton E, Digman MA, Prescher JA. Multiplexed bioluminescence microscopy via phasor analysis. Nat Methods. 2022 Jul.19(7):893-898. Pubmedid: 35739310.
• Meng H, Yao W, Yin Y, Li Y, Ding Y, Wang L, Zhang M. ZG16 promotes T-cell mediated immunity through direct binding to PD-L1 in colon cancer. Biomark Res. 2022 Jul.10(1):47. Pubmedid: 35831911. Pmcid: PMC9281127.
• Daniel Grass G, Alfonso JCL, Welsh E, Ahmed KA, Teer JK, Pilon-Thomas S, Harrison LB, Cleveland JL, Mulé JJ, Eschrich SA, Enderling H, Torres-Roca JF. The Radiosensitivity Index Gene Signature Identifies Distinct Tumor Immune Microenvironment Characteristics Associated With Susceptibility to Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022 Jul.113(3):635-647. Pubmedid: 35289298. Pmcid: PMC9250625.
• Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 Jun.606(7915):797-803. Pubmedid: 35705814.
• Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, Guenot J, Markowitz J, Cleveland JL, Wright KL, List AF, Wei S, Eksioglu EA. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol Ther. 2022 Jun.30(6):2315-2326. Pubmedid: 35150889. Pmcid: PMC9171150.
• Baratchart E, Lo CH, Lynch CC, Basanta D. Integrated computational and in vivo models reveal Key Insights into macrophage behavior during bone healing. PLoS Comput Biol. 2022 May.18(5):e1009839. Pubmedid: 35559958. Pmcid: PMC9106165.
• Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
• Adhikari E, Liu Q, Burton C, Mockabee-Macias A, Lester DK, Lau E. L-fucose, a sugary regulator of antitumor immunity and immunotherapies. Mol Carcinogen. 2022 May.61(5):439-453. Pubmedid: 35107186. Pmcid: PMC9097813.
• Tian Y, Soupir A, Liu Q, Wu L, Huang CC, Park JY, Wang L. Novel role of prostate cancer risk variant rs7247241 on PPP1R14A isoform transition through allelic TF binding and CpG methylation. Hum Mol Genet. 2022 May.31(10):1610-1621. Pubmedid: 34849858. Pmcid: PMC9122641.
• Lawrence KP, Delinasios GJ, Premi S, Young AR, Cooke MS. Perspectives on Cyclobutane Pyrimidine Dimers-Rise of the Dark Dimers. Photochem Photobiol. 2022 May.98(3):609-616. Pubmedid: 34706095.
• Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2022 May.8(3):784-793. Pubmedid: 33994165.
• Tan ES, Knepper TC, Wang X, Permuth JB, Wang L, Fleming JB, Xie H. Copy Number Alterations as Novel Biomarkers and Therapeutic Targets in Colorectal Cancer. Cancers (Basel). 2022 Apr.14(9). Pubmedid: 35565354. Pmcid: PMC9101426.
• Lin HY, Tseng TS, Wang X, Fang Z, Zea AH, Wang L, Pow-Sang J, Tangen CM, Goodman PJ, Wolk A, Håkansson N, Kogevinas M, Llorca J, Brenner H, Schöttker B, Castelao JE, Gago-Dominguez M, Gamulin M, Lessel D, Claessens F, Joniau S, The Practical Consortium, Park JY. Intake Patterns of Specific Alcoholic Beverages by Prostate Cancer Status. Cancers (Basel). 2022 Apr.14(8). Pubmedid: 35454886. Pmcid: PMC9024489.
• Fernandez MR, Schaub FX, Yang C, Li W, Yun S, Schaub SK, Dorsey FC, Liu M, Steeves MA, Ballabio A, Tzankov A, Chen Z, Koomen JM, Berglund AE, Cleveland JL. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy. Cancer Res. 2022 Apr.82(7):1234-1250. Pubmedid: 35149590. Pmcid: PMC9004540.
• Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, Torres-Roca J, Karnes RJ, Schaeffer E, Freedland SJ, Spratt DE, Den RB, Rebbeck TR, Feng F. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. Eur Urol. 2022 Apr.81(4):325-330. Pubmedid: 33303244.
• Ionescu F, Zhang J, Wang L. Clinical Applications of Liquid Biopsy in Prostate Cancer: From Screening to Predictive Biomarker. Cancers (Basel). 2022 Mar.14(7). Pubmedid: 35406500. Pmcid: PMC8996910.